You are here

Novartis

Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: 'It's A Challenge We Have To Solve'

Forbes

Thu, 11/29/18 - 11:11 am

Novartis HQ is pulling up its roots in the UK and moving to a new biotech campus in London

Endpoints

Wed, 11/28/18 - 11:32 am

Novartis/Spark’s sight gene therapy approved in EU

Pharmaforum

Fri, 11/23/18 - 01:16 pm

Spark Therapeutics

US benefits manager baulks after Novartis values gene therapy at $4-5 mln

Yahoo/Reuters

Fri, 11/23/18 - 01:12 pm

Express Scripts

spinal muscular atrophy

A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries

BioSpace

Fri, 11/23/18 - 01:08 pm

developing countries

Novartis confident in Gilenya despite FDA call out

Biopharma Dive

Wed, 11/21/18 - 01:09 pm

multiple sclerosis

Novartis CEO Is Going All in With Some Big Bets on R&D

BioSpace

Wed, 11/21/18 - 12:18 pm

Novartis focusing on cutting CAR-T costs ahead of EU launches

Pharmaforum

Tue, 11/20/18 - 11:51 am

Novartis' blood disorder drug gets FDA approval for expanded use

Reuters

Mon, 11/19/18 - 11:39 pm

severe aplastic anemia

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Mon, 11/19/18 - 11:29 am

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Novartis’ CAR-T cancer drug available on NHS to young people

Pharmaforum

Sat, 11/17/18 - 12:34 pm

refractory B-cell acute lymphoblastic leukemia

It's Lights Out For Novartis And Verily's Glucose Monitoring 'Smart Lens' Project

Forbes

Fri, 11/16/18 - 07:57 pm

blood glucose monitoring

Novartis Calls for FDA Enforcement Against Biosimilar Misinformation

RAPS.org

Thu, 11/15/18 - 11:42 pm

citizen petitions

Novartis 'completely committed' to Sandoz, has no split-off plan

Yahoo/Reuters

Thu, 11/15/18 - 11:20 am

Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Fierce Pharma

Wed, 11/14/18 - 11:57 am

Ionis, Akcea succeed in heart drug trial, setting up Novartis decision

Biopharma Dive

Tue, 11/13/18 - 10:13 pm

Akcea Therapeutics

Ionis Pharmaceuticals

clinical trials

AKCEA-APO(a)-Lrx

Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study

Endpoints

Mon, 11/12/18 - 11:49 pm

As Novartis' other cancer launches struggle, Lutathera gets off to flying start

Fierce Pharma

Fri, 11/9/18 - 11:43 am

neuroendocrine tumors

Novartis Plans for 60 Regulatory Filings Over the Next Three Years

BioSpace

Tue, 11/6/18 - 09:41 am

drug development

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

Endpoints

Tue, 11/6/18 - 12:27 am

spinal muscular atrophy

Pages